Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Robert Wayne Yeh, M.D.

Concepts

This page shows the publications Robert Yeh has written about Humans.
Connection Strength

1.960
  1. 'State of the Art' PCI: bridging the implementation gap. Eur Heart J. 2022 Mar 31; 43(13):1317-1319.
    View in: PubMed
    Score: 0.011
  2. DES and DAPT in Evolution: Will Clinical Guidelines Follow? JACC Cardiovasc Interv. 2022 02 14; 15(3):278-281.
    View in: PubMed
    Score: 0.011
  3. Days at Home After Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients. JAMA Cardiol. 2022 01 01; 7(1):110-112.
    View in: PubMed
    Score: 0.011
  4. Patent Foramen Ovale Closure-Harnessing Clinical Trial Evidence to Inform Individualized Treatment Decisions. JAMA. 2021 12 14; 326(22):2265-2267.
    View in: PubMed
    Score: 0.011
  5. Role of Frailty in Identifying Benefit From Transcatheter Versus Surgical Aortic Valve Replacement. Circ Cardiovasc Qual Outcomes. 2021 12; 14(12):e008566.
    View in: PubMed
    Score: 0.011
  6. Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings From the EXTEND-DAPT Study. Circulation. 2022 01 11; 145(2):97-106.
    View in: PubMed
    Score: 0.011
  7. Applicability of Transcatheter Aortic Valve Replacement Trials to Real-World Clinical Practice: Findings From EXTEND-CoreValve. JACC Cardiovasc Interv. 2021 10 11; 14(19):2112-2123.
    View in: PubMed
    Score: 0.011
  8. Population Trends in Rates of Percutaneous Coronary Interventions, 2010 to 2017. JAMA Cardiol. 2021 10 01; 6(10):1219-1220.
    View in: PubMed
    Score: 0.011
  9. Identification of Frailty Using a Claims-Based Frailty Index in the CoreValve Studies: Findings from the EXTEND-FRAILTY Study. J Am Heart Assoc. 2021 10 05; 10(19):e022150.
    View in: PubMed
    Score: 0.011
  10. Long-term safety of drug-coated devices for peripheral revascularisation. EuroIntervention. 2021 Sep 20; 17(7):590-598.
    View in: PubMed
    Score: 0.011
  11. Effect of intensive versus limited monitoring on clinical trial conduct and outcomes: A randomized trial. Am Heart J. 2022 01; 243:77-86.
    View in: PubMed
    Score: 0.011
  12. Association Between Diagnosis Code Expansion and Changes in 30-Day Risk-Adjusted Outcomes for Cardiovascular Diseases. J Am Heart Assoc. 2021 08 17; 10(16):e020668.
    View in: PubMed
    Score: 0.011
  13. Comparative Outcomes of Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction Among Medicare Beneficiaries With Multivessel Coronary Artery Disease: An National Cardiovascular Data Registry Research to Practice Project. Circ Cardiovasc Interv. 2021 08; 14(8):e010323.
    View in: PubMed
    Score: 0.011
  14. Long-term outcomes of percutaneous coronary intervention for in-stent restenosis among Medicare beneficiaries. EuroIntervention. 2021 Aug 06; 17(5):e380-e387.
    View in: PubMed
    Score: 0.011
  15. Longitudinal Assessment of Safety of Femoropopliteal Endovascular Treatment With Paclitaxel-Coated Devices Among Medicare Beneficiaries: The SAFE-PAD Study. JAMA Intern Med. 2021 08 01; 181(8):1071-1080.
    View in: PubMed
    Score: 0.011
  16. Rationale and design of a randomized study comparing the agent drug coated balloon to plain old balloon angioplasty in patients with In-stent restenosis. Am Heart J. 2021 11; 241:101-107.
    View in: PubMed
    Score: 0.011
  17. Comparing Baseline Data From Registries With Trials: Evidence From the CathPCI Registry and DAPT Study. JACC Cardiovasc Interv. 2021 06 28; 14(12):1386-1388.
    View in: PubMed
    Score: 0.011
  18. Temporal Changes and Institutional Variation in Use of Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction With Multivessel Coronary Artery Disease in the United States: An NCDR Research to Practice Project. JAMA Cardiol. 2021 05 01; 6(5):574-580.
    View in: PubMed
    Score: 0.010
  19. Prognosis of Claims- Versus Trial-Based Ischemic and Bleeding Events Beyond 1 Year After Coronary Stenting. J Am Heart Assoc. 2021 03 16; 10(6):e018744.
    View in: PubMed
    Score: 0.010
  20. Misclassification of Hospital Performance Under the Hospital Readmissions Reduction Program: Implications for Value-Based Programs. JAMA Cardiol. 2021 03 01; 6(3):332-335.
    View in: PubMed
    Score: 0.010
  21. Cardiovascular Deaths During the COVID-19 Pandemic in the United States. J Am Coll Cardiol. 2021 01 19; 77(2):159-169.
    View in: PubMed
    Score: 0.010
  22. Comparability of Event Adjudication Versus Administrative Billing Claims for Outcome Ascertainment in the DAPT Study: Findings From the EXTEND-DAPT Study. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e006589.
    View in: PubMed
    Score: 0.010
  23. Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2021 03; 97(4):569-578.
    View in: PubMed
    Score: 0.010
  24. Evaluation of Hospital Performance Using the Excess Days in Acute Care Measure in the Hospital Readmissions Reduction Program. Ann Intern Med. 2021 01; 174(1):86-92.
    View in: PubMed
    Score: 0.010
  25. Revascularization Practices and Outcomes in Patients With Multivessel Coronary Artery Disease Who Presented With Acute Myocardial Infarction and Cardiogenic Shock in the US, 2009-2018. JAMA Intern Med. 2020 10 01; 180(10):1317-1327.
    View in: PubMed
    Score: 0.010
  26. Use of etomidate in patients with heart failure undergoing noncardiac surgery. Br J Anaesth. 2020 12; 125(6):943-952.
    View in: PubMed
    Score: 0.010
  27. A Simple Formula to Estimate Parathyroid Weight on 4D-CT, Predict Pathologic Weight, and Diagnose Parathyroid Adenoma in Patients with Primary Hyperparathyroidism. AJNR Am J Neuroradiol. 2020 09; 41(9):1690-1697.
    View in: PubMed
    Score: 0.010
  28. Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. Circulation. 2020 07 21; 142(3):306-308.
    View in: PubMed
    Score: 0.010
  29. Validation of Administrative Claims to Ascertain Outcomes in Pivotal Trials of Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv. 2020 08 10; 13(15):1777-1785.
    View in: PubMed
    Score: 0.010
  30. Prevalence of angina and use of medical therapy among US adults: A nationally representative estimate. Am Heart J. 2020 10; 228:44-46.
    View in: PubMed
    Score: 0.010
  31. Mitral Valve Surgical Volume and Transcatheter Mitral Valve Repair Outcomes: Impact of a Proposed Volume Requirement on Geographic Access. J Am Heart Assoc. 2020 06 02; 9(11):e016140.
    View in: PubMed
    Score: 0.010
  32. Use of Administrative Claims to Assess Outcomes and Treatment Effect in Randomized Clinical Trials for Transcatheter Aortic Valve Replacement: Findings From the EXTEND Study. Circulation. 2020 07 21; 142(3):203-213.
    View in: PubMed
    Score: 0.010
  33. Weighing the potential late benefits versus early hazard associated with bioresorbable vascular scaffolds in percutaneous coronary interventions: a Markov decision analytic model. Coron Artery Dis. 2020 05; 31(3):230-236.
    View in: PubMed
    Score: 0.010
  34. Quality Measure Development and Associated Spending by the Centers for Medicare & Medicaid Services. JAMA. 2020 04 28; 323(16):1614-1616.
    View in: PubMed
    Score: 0.010
  35. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Circ Cardiovasc Qual Outcomes. 2020 03; 13(3):e006275.
    View in: PubMed
    Score: 0.010
  36. The DAPT Score Uncouples Bleeding and Ischemic Risk…Again. JACC Cardiovasc Interv. 2020 03 09; 13(5):647-650.
    View in: PubMed
    Score: 0.010
  37. Short DAPT duration after ACS - not for the faint of heart. EuroIntervention. 2019 Dec 06; 15(11):e943-e944.
    View in: PubMed
    Score: 0.009
  38. Relative Effects of the Hospital Readmissions Reduction Program on Hospitals That Serve Poorer Patients. Med Care. 2019 12; 57(12):968-976.
    View in: PubMed
    Score: 0.009
  39. Thirty-Day Spending and Outcomes for an Episode of Pneumonia Care Among Medicare Beneficiaries. Chest. 2020 05; 157(5):1241-1249.
    View in: PubMed
    Score: 0.009
  40. Comparison of Clinical Trials and Administrative Claims to Identify Stroke Among Patients Undergoing Aortic Valve Replacement: Findings From the EXTEND Study. Circ Cardiovasc Interv. 2019 11; 12(11):e008231.
    View in: PubMed
    Score: 0.009
  41. Association of Frailty With 30-Day Outcomes for Acute Myocardial Infarction, Heart Failure, and Pneumonia Among Elderly Adults. JAMA Cardiol. 2019 11 01; 4(11):1084-1091.
    View in: PubMed
    Score: 0.009
  42. Myocardial Perfusion After Coronary Chronic Total Occlusion Percutaneous Coronary Intervention: Does It Matter to Myocytes How You Cross the Lesion? Circ Cardiovasc Interv. 2019 11; 12(11):e008568.
    View in: PubMed
    Score: 0.009
  43. Geographic Patterns of Growth for Transcatheter Aortic Valve Replacement in the United States. Circulation. 2019 09 10; 140(11):969-971.
    View in: PubMed
    Score: 0.009
  44. Examining the Operator Learning Curve for Percutaneous Coronary Intervention of Chronic Total Occlusions. Circ Cardiovasc Interv. 2019 08; 12(8):e007877.
    View in: PubMed
    Score: 0.009
  45. Hospital revisits within 30 days after discharge for medical conditions targeted by the Hospital Readmissions Reduction Program in the United States: national retrospective analysis. BMJ. 2019 08 12; 366:l4563.
    View in: PubMed
    Score: 0.009
  46. Readmission Penalties: The Authors Reply. Health Aff (Millwood). 2019 08; 38(8):1410.
    View in: PubMed
    Score: 0.009
  47. Frailty and related outcomes in patients undergoing transcatheter valve therapies in a nationwide cohort. Eur Heart J. 2019 07 14; 40(27):2231-2239.
    View in: PubMed
    Score: 0.009
  48. Trends in isolated aortic valve replacement in the United States in the early phase of expansion of TAVR. Int J Cardiol. 2019 10 01; 292:68-72.
    View in: PubMed
    Score: 0.009
  49. Health Insurance and Mobile Health Devices: Opportunities and Concerns. JAMA. 2019 May 14; 321(18):1767-1768.
    View in: PubMed
    Score: 0.009
  50. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
    View in: PubMed
    Score: 0.009
  51. Association of Survival With Femoropopliteal Artery Revascularization With Drug-Coated Devices. JAMA Cardiol. 2019 04 01; 4(4):332-340.
    View in: PubMed
    Score: 0.009
  52. Patient Readmission Rates For All Insurance Types After Implementation Of The Hospital Readmissions Reduction Program. Health Aff (Millwood). 2019 04; 38(4):585-593.
    View in: PubMed
    Score: 0.009
  53. Public Reporting of Percutaneous Coronary Intervention Outcomes: Institutional Costs and Physician Burden. J Am Coll Cardiol. 2019 05 28; 73(20):2604-2608.
    View in: PubMed
    Score: 0.009
  54. Depression and Angina Among Patients Undergoing Chronic Total Occlusion Percutaneous Coronary Intervention: The OPEN-CTO Registry. JACC Cardiovasc Interv. 2019 04 08; 12(7):651-658.
    View in: PubMed
    Score: 0.009
  55. Validating the use of registries and claims data to support randomized trials: Rationale and design of the Extending Trial-Based Evaluations of Medical Therapies Using Novel Sources of Data (EXTEND) Study. Am Heart J. 2019 06; 212:64-71.
    View in: PubMed
    Score: 0.009
  56. Extracorporeal Membrane Oxygenation Use in Cardiogenic Shock: Impact of Age on In-Hospital Mortality, Length of Stay, and Costs. Crit Care Med. 2019 03; 47(3):e214-e221.
    View in: PubMed
    Score: 0.009
  57. Drug-Eluting Stent Implantation and Long-Term Survival Following Peripheral Artery Revascularization. J Am Coll Cardiol. 2019 05 28; 73(20):2636-2638.
    View in: PubMed
    Score: 0.009
  58. Temporal Trends in Unstable Angina Diagnosis Codes for Outpatient Percutaneous Coronary Interventions. JAMA Intern Med. 2019 02 01; 179(2):259-261.
    View in: PubMed
    Score: 0.009
  59. Contemporary Use and Trends in Unprotected Left Main Coronary Artery Percutaneous Coronary Intervention in the United States: An Analysis of the National Cardiovascular Data Registry Research to Practice Initiative. JAMA Cardiol. 2019 02 01; 4(2):100-109.
    View in: PubMed
    Score: 0.009
  60. Association of Physician Variation in Use of Manual Aspiration Thrombectomy With Outcomes Following Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction: The National Cardiovascular Data Registry CathPCI Registry. JAMA Cardiol. 2019 02 01; 4(2):110-118.
    View in: PubMed
    Score: 0.009
  61. Reply: Trends in Isolated Surgical Aortic Valve Replacement. JACC Cardiovasc Interv. 2019 01 14; 12(1):108-109.
    View in: PubMed
    Score: 0.009
  62. SCOT-HEART: Does it live up to the PROMISE? J Cardiovasc Comput Tomogr. 2019 May - Jun; 13(3):48-50.
    View in: PubMed
    Score: 0.009
  63. Association of Hospital Surgical Aortic Valve Replacement Quality With 30-Day and 1-Year Mortality After Transcatheter Aortic Valve Replacement. JAMA Cardiol. 2019 01 01; 4(1):16-22.
    View in: PubMed
    Score: 0.009
  64. Hospital Variation in the Utilization of Short-Term Nondurable Mechanical Circulatory Support in Myocardial Infarction Complicated by Cardiogenic Shock. Circ Cardiovasc Interv. 2019 01; 12(1):e007270.
    View in: PubMed
    Score: 0.009
  65. Association of the Hospital Readmissions Reduction Program With Mortality Among Medicare Beneficiaries Hospitalized for Heart Failure, Acute Myocardial Infarction, and Pneumonia. JAMA. 2018 12 25; 320(24):2542-2552.
    View in: PubMed
    Score: 0.009
  66. Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial. BMJ. 2018 Dec 13; 363:k5094.
    View in: PubMed
    Score: 0.009
  67. Re: Multivessel Percutaneous Coronary Intervention in Patients with ST-Segment Elevation Myocardial Infarction with Cardiogenic Shock. Epidemiology. 2018 11; 29(6):e59-e60.
    View in: PubMed
    Score: 0.009
  68. Patient-Reported Outcomes in Cardiology. Circ Cardiovasc Qual Outcomes. 2018 11; 11(11):e004794.
    View in: PubMed
    Score: 0.009
  69. Trends in Isolated Surgical Aortic Valve Replacement According to Hospital-Based Transcatheter Aortic Valve Replacement Volumes. JACC Cardiovasc Interv. 2018 11 12; 11(21):2148-2156.
    View in: PubMed
    Score: 0.009
  70. The Value of Claims-Based Nontraditional Risk Factors in Predicting Long-term Mortality After MitraClip Procedure. Can J Cardiol. 2018 12; 34(12):1648-1654.
    View in: PubMed
    Score: 0.009
  71. Impact of a Claims-Based Frailty Indicator on the Prediction of Long-Term Mortality After Transcatheter Aortic Valve Replacement in Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2018 10; 11(10):e005048.
    View in: PubMed
    Score: 0.009
  72. Prevalence and Outcomes of Isolated Tricuspid Valve Surgery Among Medicare Beneficiaries. Am J Cardiol. 2019 01 01; 123(1):132-138.
    View in: PubMed
    Score: 0.009
  73. Meta-Analysis of Bleeding Risk Prediction Scores in Patients After Percutaneous Coronary Intervention on Dual Antiplatelet Therapy. Am J Cardiol. 2018 12 01; 122(11):1843-1852.
    View in: PubMed
    Score: 0.009
  74. Inadequate Surrogates for Imperfect Quality Measures. Circ Cardiovasc Interv. 2018 09; 11(9):e007216.
    View in: PubMed
    Score: 0.009
  75. Inferior Vena Cava Filters and Mortality: Is It the Underlying Process, the Patient, or the Device? JAMA Netw Open. 2018 07 06; 1(3):e180453.
    View in: PubMed
    Score: 0.009
  76. A Survey of Interventional Cardiologists' Attitudes and Beliefs About Public Reporting of Percutaneous Coronary Intervention. JAMA Cardiol. 2018 07 01; 3(7):629-634.
    View in: PubMed
    Score: 0.009
  77. Exposure Misclassification in Observational Studies: Setting New Standards. Circ Cardiovasc Qual Outcomes. 2018 07; 11(7):e004939.
    View in: PubMed
    Score: 0.009
  78. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States. J Am Heart Assoc. 2018 06 26; 7(13).
    View in: PubMed
    Score: 0.009
  79. State Variation in the Use of Non-Acute Coronary Angiograms and Coronary Revascularization Procedures. JACC Cardiovasc Interv. 2018 05 14; 11(9):912-913.
    View in: PubMed
    Score: 0.008
  80. Complete vs Incomplete Revascularization During Percutaneous Coronary Intervention and Improved Survival-The Key Is Immortality. JAMA Cardiol. 2018 05 01; 3(5):443-444.
    View in: PubMed
    Score: 0.008
  81. 30-Day Episode Payments and Heart Failure Outcomes Among Medicare Beneficiaries. JACC Heart Fail. 2018 05; 6(5):379-387.
    View in: PubMed
    Score: 0.008
  82. National trends, predictors of use, and in-hospital outcomes in mechanical circulatory support for cardiogenic shock. EuroIntervention. 2018 04 06; 13(18):e2152-e2159.
    View in: PubMed
    Score: 0.008
  83. Academic Cardiology and Social Media: Navigating the Wisdom and Madness of the Crowd. Circ Cardiovasc Qual Outcomes. 2018 04; 11(4):e004736.
    View in: PubMed
    Score: 0.008
  84. Applicability of Publicly Reported Hospital Readmission Measures to Unreported Conditions and Other Patient Populations: A Cross-sectional All-Payer Study. Ann Intern Med. 2018 05 01; 168(9):631-639.
    View in: PubMed
    Score: 0.008
  85. Association Between 30-Day Episode Payments and Acute Myocardial Infarction Outcomes Among Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2018 03; 11(3):e004397.
    View in: PubMed
    Score: 0.008
  86. Utilization, In-Hospital Mortality, and 30-Day Readmission After Percutaneous Mitral Valve Repair in the United States Shortly After Device Approval. Am J Cardiol. 2018 06 01; 121(11):1365-1372.
    View in: PubMed
    Score: 0.008
  87. Safety and effectiveness of zotarolimus-eluting stents for percutaneous coronary intervention: a systematic review. Future Cardiol. 2018 05 01; 14(3):251-267.
    View in: PubMed
    Score: 0.008
  88. Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Prog Cardiovasc Dis. 2018 Jan - Feb; 60(4-5):491-499.
    View in: PubMed
    Score: 0.008
  89. Understanding How to Improve Quality and Value for Patients With Acute Myocardial Infarction. JAMA Cardiol. 2018 02 01; 3(2):102-103.
    View in: PubMed
    Score: 0.008
  90. Mortality, Length of Stay, and Cost of Weekend Admissions. J Hosp Med. 2018 07 01; 13(7):476-481.
    View in: PubMed
    Score: 0.008
  91. Challenges of Assessing Therapeutic or Diagnostic Outcomes with Observational Data. Am J Med. 2018 02; 131(2):206-210.
    View in: PubMed
    Score: 0.008
  92. Readmissions After Revascularization Procedures for Peripheral Arterial Disease: A Nationwide Cohort Study. Ann Intern Med. 2018 01 16; 168(2):93-99.
    View in: PubMed
    Score: 0.008
  93. Brachial-ankle pulse wave velocity as a marker of adverse events following non-ST-elevation myocardial infarction: a new standard in risk stratification? Coron Artery Dis. 2017 12; 28(8):634-635.
    View in: PubMed
    Score: 0.008
  94. High-Risk Percutaneous Coronary Intervention in Public Reporting States: the Evidence, Exclusion of Critically Ill Patients, and Implications. Curr Heart Fail Rep. 2017 12; 14(6):514-518.
    View in: PubMed
    Score: 0.008
  95. Should We Care About Short-Term Readmissions After Percutaneous Coronary Intervention? Circ Cardiovasc Interv. 2017 12; 10(12).
    View in: PubMed
    Score: 0.008
  96. Lesion Complexity and Outcomes of Extended Dual Antiplatelet Therapy After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2017 Oct 31; 70(18):2213-2223.
    View in: PubMed
    Score: 0.008
  97. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing. Circulation. 2017 Dec 05; 136(23):2210-2219.
    View in: PubMed
    Score: 0.008
  98. Incentivizing Transradial Access for Primary Percutaneous Coronary Intervention While Maintaining Timely Reperfusion. JAMA Cardiol. 2017 10 01; 2(10):1057-1058.
    View in: PubMed
    Score: 0.008
  99. Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circ Cardiovasc Qual Outcomes. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.008
  100. Public Reporting of Percutaneous Coronary Intervention Mortality in New York State: Are We Helping Our Patients? Circ Cardiovasc Qual Outcomes. 2017 09; 10(9).
    View in: PubMed
    Score: 0.008
  101. Seasonality and Readmission after Heart Failure, Myocardial Infarction, and Pneumonia. Health Serv Res. 2018 08; 53(4):2185-2202.
    View in: PubMed
    Score: 0.008
  102. Target Vessel Revascularization and Territory of Myocardial Ischemia in Patients With Chronic Total Occlusions. J Am Coll Cardiol. 2017 08 29; 70(9):1196-1197.
    View in: PubMed
    Score: 0.008
  103. Individualizing dual antiplatelet therapy duration after percutaneous coronary intervention: from randomized control trials to personalized medicine. Expert Rev Cardiovasc Ther. 2017 Sep; 15(9):681-693.
    View in: PubMed
    Score: 0.008
  104. Comparison of 30-Day Readmission Rates After Hospitalization for Acute Myocardial Infarction in Men Versus Women. Am J Cardiol. 2017 Oct 01; 120(7):1070-1076.
    View in: PubMed
    Score: 0.008
  105. Short-term rehospitalization across the spectrum of age and insurance types in the United States. PLoS One. 2017; 12(7):e0180767.
    View in: PubMed
    Score: 0.008
  106. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Cardiol Clin. 2017 May; 35(2):281-296.
    View in: PubMed
    Score: 0.008
  107. Management of Patients With Cardiac Arrest Complicating Myocardial Infarction in New York Before and After Public Reporting Policy Changes. Circ Cardiovasc Interv. 2017 May; 10(5).
    View in: PubMed
    Score: 0.008
  108. The risk of bleeding with the use of antiplatelet agents for the treatment of cardiovascular disease. Expert Opin Drug Saf. 2017 May; 16(5):561-572.
    View in: PubMed
    Score: 0.008
  109. The Effect of Survivor Bias on Observational Analyses of Staged PCI in STEMI Patients. JACC Cardiovasc Interv. 2017 03 27; 10(6):629-630.
    View in: PubMed
    Score: 0.008
  110. Utilization and outcomes of transcatheter aortic valve replacement in the United States shortly after device approval. Catheter Cardiovasc Interv. 2017 Nov 01; 90(5):830-838.
    View in: PubMed
    Score: 0.008
  111. Decision Tools to Improve Personalized Care in Cardiovascular Disease: Moving the Art of Medicine Toward Science. Circulation. 2017 03 21; 135(12):1097-1100.
    View in: PubMed
    Score: 0.008
  112. New-Generation Coronary Stents: Current Data and Future Directions. Curr Atheroscler Rep. 2017 Mar; 19(3):14.
    View in: PubMed
    Score: 0.008
  113. Quality of Care at Hospitals Identified as Outliers in Publicly Reported Mortality Statistics for Percutaneous Coronary Intervention. Circulation. 2017 May 16; 135(20):1897-1907.
    View in: PubMed
    Score: 0.008
  114. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program. JACC Cardiovasc Interv. 2017 02 13; 10(3):247-254.
    View in: PubMed
    Score: 0.008
  115. Readmission Rates After Passage of the Hospital Readmissions Reduction Program: A Pre-Post Analysis. Ann Intern Med. 2017 Mar 07; 166(5):324-331.
    View in: PubMed
    Score: 0.008
  116. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC Cardiovasc Interv. 2016 12 12; 9(23):2376-2386.
    View in: PubMed
    Score: 0.008
  117. Use of Chronic Oral Anticoagulation and Associated Outcomes Among Patients Undergoing Percutaneous Coronary Intervention. J Am Heart Assoc. 2016 10 17; 5(10).
    View in: PubMed
    Score: 0.008
  118. Treatment and Outcomes of Acute Myocardial Infarction Complicated by Shock After Public Reporting Policy Changes in New York. JAMA Cardiol. 2016 09 01; 1(6):648-54.
    View in: PubMed
    Score: 0.008
  119. Letter by Secemsky et al Regarding Article, "Relationship Between Femoral Vascular Closure Devices and Short-Term Mortality From 271?845 Percutaneous Coronary Intervention Procedures Performed in the United Kingdom Between 2006 and 2011: A Propensity Score-Corrected Analysis From the British Cardiovascular Intervention Society". Circ Cardiovasc Interv. 2016 09; 9(9).
    View in: PubMed
    Score: 0.008
  120. Contemporary Drug-Eluting Stent Platforms: Design, Safety, and Clinical Efficacy. Interv Cardiol Clin. 2016 07; 5(3):331-347.
    View in: PubMed
    Score: 0.007
  121. Incidence and predictors of incomplete revascularization in a contemporary cohort. Coron Artery Dis. 2016 May; 27(3):191-8.
    View in: PubMed
    Score: 0.007
  122. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA. 2016 Apr 26; 315(16):1735-49.
    View in: PubMed
    Score: 0.007
  123. Effectiveness of Arterial Closure Devices for Preventing Complications With Percutaneous Coronary Intervention: An Instrumental Variable Analysis. Circ Cardiovasc Interv. 2016 Apr; 9(4):e003464.
    View in: PubMed
    Score: 0.007
  124. Management of Complications. Interv Cardiol Clin. 2016 04; 5(2):201-209.
    View in: PubMed
    Score: 0.007
  125. Letter by Wasfy et al Regarding Article, "Facility Level Variation in Hospitalization, Mortality, and Costs in the 30 Days After Percutaneous Coronary Intervention: Insights on Short-Term Healthcare Value From the Veterans Affairs Clinical Assessment, Reporting, and Tracking System (VA CART) Program". Circulation. 2016 Feb 02; 133(5):e376.
    View in: PubMed
    Score: 0.007
  126. Future of the PCI Readmission Metric. Circ Cardiovasc Qual Outcomes. 2016 Mar; 9(2):186-9.
    View in: PubMed
    Score: 0.007
  127. Feasibility of a Tablet Computer System to Collect Patient-reported Symptom Severity in Patients Undergoing Diagnostic Coronary Angiography. Crit Pathw Cardiol. 2015 Dec; 14(4):139-45.
    View in: PubMed
    Score: 0.007
  128. Reply: Analysis of Dual Antiplatelet Therapy. J Am Coll Cardiol. 2015 Nov 03; 66(18):2056.
    View in: PubMed
    Score: 0.007
  129. Mortality risk with dual antiplatelet therapy? Lancet. 2015 Oct 17; 386(10003):1533-4.
    View in: PubMed
    Score: 0.007
  130. Angina Severity, Depression, and Response to Percutaneous Revascularization in Patients With Chronic Total Occlusion of Coronary Arteries. J Invasive Cardiol. 2016 Feb; 28(2):44-51.
    View in: PubMed
    Score: 0.007
  131. Predicting the Presence of an Acute Coronary Lesion Among Patients Resuscitated From Cardiac Arrest. Circ Cardiovasc Interv. 2015 Oct; 8(10).
    View in: PubMed
    Score: 0.007
  132. Response to Letter Regarding Article, "Surgical Ineligibility and Mortality Among Patients With Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention". Circulation. 2015 Sep 22; 132(12):e156.
    View in: PubMed
    Score: 0.007
  133. Reply: Impact of Clinical Presentation on Dual Antiplatelet Therapy Duration: Let's Re-Evaluate Our Priorities. J Am Coll Cardiol. 2015 Sep 08; 66(10):1204-5.
    View in: PubMed
    Score: 0.007
  134. Enhancing the Prediction of 30-Day Readmission After Percutaneous Coronary Intervention Using Data Extracted by Querying of the Electronic Health Record. Circ Cardiovasc Qual Outcomes. 2015 Sep; 8(5):477-85.
    View in: PubMed
    Score: 0.007
  135. Assessing the optimal strategy for dual antiplatelet therapy. Expert Rev Cardiovasc Ther. 2015 Oct; 13(10):1067-9.
    View in: PubMed
    Score: 0.007
  136. Dual antiplatelet therapy duration and mortality - Authors' reply. Lancet. 2015 May 30; 385(9983):2149-50.
    View in: PubMed
    Score: 0.007
  137. Hospital variation in carotid stenting outcomes. JACC Cardiovasc Interv. 2015 May; 8(6):858-863.
    View in: PubMed
    Score: 0.007
  138. Public reporting in cardiovascular medicine: accountability, unintended consequences, and promise for improvement. Circulation. 2015 Apr 28; 131(17):1518-27.
    View in: PubMed
    Score: 0.007
  139. Proximal versus distal embolic protection for carotid artery stenting: a national cardiovascular data registry analysis. JACC Cardiovasc Interv. 2015 Apr 20; 8(4):609-15.
    View in: PubMed
    Score: 0.007
  140. Association between public reporting of outcomes with procedural management and mortality for patients with acute myocardial infarction. J Am Coll Cardiol. 2015 Mar 24; 65(11):1119-26.
    View in: PubMed
    Score: 0.007
  141. Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy. Eur Heart J. 2015 May 21; 36(20):1216-8.
    View in: PubMed
    Score: 0.007
  142. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. J Am Coll Cardiol. 2015 May 26; 65(20):2211-21.
    View in: PubMed
    Score: 0.007
  143. Dual Antiplatelet Therapy Duration Following Coronary Stenting. [Corrected]. J Am Coll Cardiol. 2015 Mar 03; 65(8):787-790.
    View in: PubMed
    Score: 0.007
  144. Population trends in rates of coronary revascularization. JAMA Intern Med. 2015 Mar; 175(3):454-6.
    View in: PubMed
    Score: 0.007
  145. Evaluating the generalizability of a large streamlined cardiovascular trial: comparing hospitals and patients in the dual antiplatelet therapy study versus the National Cardiovascular Data Registry. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):96-102.
    View in: PubMed
    Score: 0.007
  146. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015 Feb 28; 385(9970):792-8.
    View in: PubMed
    Score: 0.007
  147. Culprit only, multivessel, or staged multivessel intervention in STEMI: new insights or insurmountable methodologic obstacles? Catheter Cardiovasc Interv. 2014 Nov 15; 84(6):923-4.
    View in: PubMed
    Score: 0.007
  148. Surgical ineligibility and mortality among patients with unprotected left main or multivessel coronary artery disease undergoing percutaneous coronary intervention. Circulation. 2014 Dec 23; 130(25):2295-301.
    View in: PubMed
    Score: 0.007
  149. Public reporting and coronary revascularization: risk and benefit. Coron Artery Dis. 2014 Nov; 25(7):619-26.
    View in: PubMed
    Score: 0.007
  150. Clinical preventability of 30-day readmission after percutaneous coronary intervention. J Am Heart Assoc. 2014 Sep 26; 3(5):e001290.
    View in: PubMed
    Score: 0.007
  151. Blood transfusion in myocardial infarction: opening old wounds for comparative-effectiveness research. J Am Coll Cardiol. 2014 Aug 26; 64(8):820-2.
    View in: PubMed
    Score: 0.007
  152. Defining unavoidable delays in primary percutaneous coronary intervention: discordance among patients excluded from National Cardiovascular Quality Registries. J Am Heart Assoc. 2014 Jun 25; 3(3):e000944.
    View in: PubMed
    Score: 0.006
  153. Clinical prediction model suitable for assessing hospital quality for patients undergoing carotid endarterectomy. J Am Heart Assoc. 2014 Jun 17; 3(3):e000728.
    View in: PubMed
    Score: 0.006
  154. Association between operator procedure volume and patient outcomes in percutaneous coronary intervention: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2014 Jul; 7(4):560-6.
    View in: PubMed
    Score: 0.006
  155. Delay in reperfusion with transradial percutaneous coronary intervention for ST-elevation myocardial infarction: Might some delays be acceptable? Am Heart J. 2014 Jul; 168(1):103-9.
    View in: PubMed
    Score: 0.006
  156. Population trends from 2000-2011 in nuclear myocardial perfusion imaging use. JAMA. 2014 Mar 26; 311(12):1248-9.
    View in: PubMed
    Score: 0.006
  157. Reply: Bleeding after PCI, vascular access, and falsification endpoints in observational studies. J Am Coll Cardiol. 2014 Jun 17; 63(23):2587-2588.
    View in: PubMed
    Score: 0.006
  158. Cardiovascular event risk after noncardiac surgery. JAMA. 2014 Feb 05; 311(5):525.
    View in: PubMed
    Score: 0.006
  159. Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. Catheter Cardiovasc Interv. 2014 May 01; 83(6):975-83.
    View in: PubMed
    Score: 0.006
  160. Comparative effectiveness of commonly used devices for carotid artery stenting: an NCDR Analysis (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2014 Feb; 7(2):171-177.
    View in: PubMed
    Score: 0.006
  161. High-risk percutaneous coronary intervention in the era of public reporting: clinical and ethical considerations in the care of an elderly patient with critical left main disease and shock. Circulation. 2014 Jan 14; 129(2):258-65.
    View in: PubMed
    Score: 0.006
  162. Causes of short-term readmission after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014 Feb; 7(1):97-103.
    View in: PubMed
    Score: 0.006
  163. Impact of academic year timing on percutaneous coronary intervention outcomes at training institutions. J Am Coll Cardiol. 2014 Mar 18; 63(10):1025-6.
    View in: PubMed
    Score: 0.006
  164. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circ Cardiovasc Qual Outcomes. 2014 Jan; 7(1):118-24.
    View in: PubMed
    Score: 0.006
  165. Reporting trends and outcomes in ST-segment-elevation myocardial infarction national hospital quality assessment programs. Circulation. 2014 Jan 14; 129(2):194-202.
    View in: PubMed
    Score: 0.006
  166. Comparison of transradial versus transfemoral percutaneous coronary intervention in routine practice: evidence for the importance of "falsification hypotheses" in observational studies of comparative effectiveness. J Am Coll Cardiol. 2013 Dec 03; 62(22):2147-8.
    View in: PubMed
    Score: 0.006
  167. A prediction model to identify patients at high risk for 30-day readmission after percutaneous coronary intervention. Circ Cardiovasc Qual Outcomes. 2013 Jul; 6(4):429-35.
    View in: PubMed
    Score: 0.006
  168. Coronary chronic total occlusion in the elderly: demographic inevitability, treatment uncertainty. Catheter Cardiovasc Interv. 2013 Jul 01; 82(1):93-4.
    View in: PubMed
    Score: 0.006
  169. Risk-treatment paradox in the selection of transradial access for percutaneous coronary intervention. J Am Heart Assoc. 2013 May 24; 2(3):e000174.
    View in: PubMed
    Score: 0.006
  170. Pre-procedural risk quantification for carotid stenting using the CAS score: a report from the NCDR CARE Registry. J Am Coll Cardiol. 2012 Oct 23; 60(17):1617-22.
    View in: PubMed
    Score: 0.006
  171. Use of drug-eluting stents as a function of predicted benefit: clinical and economic implications of current practice. Arch Intern Med. 2012 Aug 13; 172(15):1145-52.
    View in: PubMed
    Score: 0.006
  172. Another view of personalized medicine: optimizing stent selection on the basis of predicted benefit in percutaneous coronary intervention. Trends Cardiovasc Med. 2012 Jan; 22(1):23-8.
    View in: PubMed
    Score: 0.006
  173. Sources of hospital variation in short-term readmission rates after percutaneous coronary intervention. Circ Cardiovasc Interv. 2012 Apr; 5(2):227-36.
    View in: PubMed
    Score: 0.006
  174. Geographic disparities in the incidence and outcomes of hospitalized myocardial infarction: does a rising tide lift all boats? Circ Cardiovasc Qual Outcomes. 2012 Mar 01; 5(2):197-204.
    View in: PubMed
    Score: 0.005
  175. Choosing methods to minimize confounding in observational studies: do the ends justify the means? Circ Cardiovasc Qual Outcomes. 2011 Nov 01; 4(6):581-3.
    View in: PubMed
    Score: 0.005
  176. Predicting the restenosis benefit of drug-eluting versus bare metal stents in percutaneous coronary intervention. Circulation. 2011 Oct 04; 124(14):1557-64.
    View in: PubMed
    Score: 0.005
  177. Accounting for the mortality benefit of drug-eluting stents in percutaneous coronary intervention: a comparison of methods in a retrospective cohort study. BMC Med. 2011 Jun 24; 9:78.
    View in: PubMed
    Score: 0.005
  178. Do postmarketing surveillance studies represent real-world populations? A comparison of patient characteristics and outcomes after carotid artery stenting. Circulation. 2011 Apr 05; 123(13):1384-90.
    View in: PubMed
    Score: 0.005
  179. Technical and procedural outcomes of the retrograde approach to chronic total occlusion interventions. EuroIntervention. 2020 12 04; 16(11):e891-e899.
    View in: PubMed
    Score: 0.005
  180. Takotsubo cardiomyopathy complicated by cardiac tamponade: classic hemodynamic findings with a new disease. Circulation. 2010 Sep 21; 122(12):1239-41.
    View in: PubMed
    Score: 0.005
  181. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010 Jun 10; 362(23):2155-65.
    View in: PubMed
    Score: 0.005
  182. Rethinking the epidemiology of acute myocardial infarction: challenges and opportunities. Arch Intern Med. 2010 May 10; 170(9):759-64.
    View in: PubMed
    Score: 0.005
  183. Anticoagulation with the direct thrombin inhibitor argatroban in patients presenting with acute coronary syndromes. Catheter Cardiovasc Interv. 2009 Aug 01; 74(2):359-64.
    View in: PubMed
    Score: 0.005
  184. Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromes. Am J Cardiol. 2007 Dec 15; 100(12):1734-8.
    View in: PubMed
    Score: 0.004
  185. Predictors for the development of elevated anti-heparin/platelet factor 4 antibody titers in patients undergoing cardiac catheterization. Am J Cardiol. 2006 Aug 01; 98(3):419-21.
    View in: PubMed
    Score: 0.004
  186. Argatroban: update. Am Heart J. 2006 Jun; 151(6):1131-8.
    View in: PubMed
    Score: 0.004
  187. Efficacy of esomeprazole in controlling reflux symptoms, intraesophageal, and intragastric pH in patients with Barrett's esophagus. Dis Esophagus. 2003; 16(3):193-8.
    View in: PubMed
    Score: 0.003
  188. Outcomes Associated With Peripheral Artery Disease in Myocardial Infarction With Cardiogenic Shock. J Am Coll Cardiol. 2022 Apr 05; 79(13):1223-1235.
    View in: PubMed
    Score: 0.003
  189. Days out of Institution after Tracheostomy and Gastrostomy Placement in Critically Ill Older Adults. Ann Am Thorac Soc. 2022 03; 19(3):424-432.
    View in: PubMed
    Score: 0.003
  190. Rural-Urban Disparities in Outcomes of Myocardial Infarction, Heart Failure, and Stroke in the United States. J Am Coll Cardiol. 2022 01 25; 79(3):267-279.
    View in: PubMed
    Score: 0.003
  191. Association of Frailty With Treatment Selection and Long-Term Outcomes Among Patients With Chronic Limb-Threatening Ischemia. J Am Heart Assoc. 2021 12 21; 10(24):e023138.
    View in: PubMed
    Score: 0.003
  192. Hospital-Level Percutaneous Coronary Intervention Performance With Simulated Risk Avoidance. J Am Coll Cardiol. 2021 11 30; 78(22):2213-2217.
    View in: PubMed
    Score: 0.003
  193. Epidemiology of Cardiogenic Shock in Hospitalized Adults With COVID-19: A Report From the American Heart Association COVID-19 Cardiovascular Disease Registry. Circ Heart Fail. 2021 12; 14(12):e008477.
    View in: PubMed
    Score: 0.003
  194. Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population. JACC Cardiovasc Interv. 2021 11 08; 14(21):2344-2349.
    View in: PubMed
    Score: 0.003
  195. Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. J Am Coll Cardiol. 2021 11 02; 78(18):1768-1778.
    View in: PubMed
    Score: 0.003
  196. National trends in utilization of thrombolytic therapy for acute pulmonary embolism. Vasc Med. 2022 02; 27(1):75-76.
    View in: PubMed
    Score: 0.003
  197. Safety and efficacy of dedicated guidewire, microcatheter, and guide catheter extension technologies for chronic total coronary occlusion revascularization: Primary results of the Teleflex Chronic Total Occlusion Study. Catheter Cardiovasc Interv. 2022 02; 99(2):263-270.
    View in: PubMed
    Score: 0.003
  198. Dissemination of Transcatheter Aortic Valve Replacement in the United States. J Am Coll Cardiol. 2021 08 24; 78(8):794-806.
    View in: PubMed
    Score: 0.003
  199. Global Chronic Total Occlusion Crossing Algorithm: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021 08 24; 78(8):840-853.
    View in: PubMed
    Score: 0.003
  200. Distal Radial Access in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the PROGRESS-CTO Registry. J Invasive Cardiol. 2021 Sep; 33(9):E717-E722.
    View in: PubMed
    Score: 0.003
  201. Intravascular Molecular-Structural Assessment of Arterial Inflammation in Preclinical Atherosclerosis Progression. JACC Cardiovasc Imaging. 2021 11; 14(11):2265-2267.
    View in: PubMed
    Score: 0.003
  202. Racial/Ethnic Disparities in Hypertension Prevalence, Awareness, Treatment, and Control in the United States, 2013 to 2018. Hypertension. 2021 12; 78(6):1719-1726.
    View in: PubMed
    Score: 0.003
  203. Association of COVID-19 Hospitalization Volume and Case Growth at US Hospitals with Patient Outcomes. Am J Med. 2021 11; 134(11):1380-1388.e3.
    View in: PubMed
    Score: 0.003
  204. Relation of the Number of Cardiovascular Conditions and Short-term Symptom Improvement After Percutaneous Coronary Intervention for Stable Angina Pectoris. Am J Cardiol. 2021 09 15; 155:1-8.
    View in: PubMed
    Score: 0.003
  205. Association of Socioeconomic Disadvantage With Mortality and Readmissions Among Older Adults Hospitalized for Pulmonary Embolism in the United States. J Am Heart Assoc. 2021 07 06; 10(13):e021117.
    View in: PubMed
    Score: 0.003
  206. Prevalence of Angina Among Primary Care Patients With Coronary Artery Disease. JAMA Netw Open. 2021 06 01; 4(6):e2112800.
    View in: PubMed
    Score: 0.003
  207. New Heart Failure After Myocardial Infarction (From the National Cardiovascular Data Registries [NCDR] Linked With All-Payer Claims). Am J Cardiol. 2021 07 15; 151:70-77.
    View in: PubMed
    Score: 0.003
  208. Racial and Ethnic Disparities in Heart and Cerebrovascular Disease Deaths During the COVID-19 Pandemic in the United States. Circulation. 2021 06 15; 143(24):2346-2354.
    View in: PubMed
    Score: 0.003
  209. Accuracy of Cardiovascular Trial Outcome Ascertainment and Treatment Effect Estimates from Routine Health Data: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes. 2021 05; 14(5):e007903.
    View in: PubMed
    Score: 0.003
  210. Longitudinal management and outcomes of acute coronary syndrome in persons living with HIV infection. Eur Heart J Qual Care Clin Outcomes. 2021 05 03; 7(3):273-279.
    View in: PubMed
    Score: 0.003
  211. Patient Selection for Intensive Blood Pressure Management Based on Benefit and Adverse Events. J Am Coll Cardiol. 2021 04 27; 77(16):1977-1990.
    View in: PubMed
    Score: 0.003
  212. Limited duration of antiarrhythmic drug use for newly diagnosed atrial fibrillation in a nationwide population under age 65. J Cardiovasc Electrophysiol. 2021 06; 32(6):1529-1537.
    View in: PubMed
    Score: 0.003
  213. Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681.
    View in: PubMed
    Score: 0.003
  214. Rural-Urban Disparities: Diabetes, Hypertension, Heart Disease, and Stroke Mortality Among Black and White Adults, 1999-2018. J Am Coll Cardiol. 2021 03 23; 77(11):1480-1481.
    View in: PubMed
    Score: 0.003
  215. Association Between the Proportion of Black Patients Cared for at Hospitals and Financial Penalties Under Value-Based Payment Programs. JAMA. 2021 03 23; 325(12):1219-1221.
    View in: PubMed
    Score: 0.003
  216. Five-year clinical outcomes of zotarolimus-eluting stents in coronary total occlusions. EuroIntervention. 2021 Mar 19; 16(16):1326-1332.
    View in: PubMed
    Score: 0.003
  217. Trends in Coded Indications for Percutaneous Coronary Interventions in Medicare and the Veterans Affairs After Implementation of Hospital-Level Reporting of Appropriate Use Criteria. Circ Cardiovasc Qual Outcomes. 2021 04; 14(4):e006887.
    View in: PubMed
    Score: 0.003
  218. Association of symptom status, myocardial viability, and clinical/anatomic risk on long-term outcomes after chronic total occlusion percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021 05 01; 97 Suppl 2:996-1008.
    View in: PubMed
    Score: 0.003
  219. Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent. Circ Cardiovasc Interv. 2021 03; 14(3):e010144.
    View in: PubMed
    Score: 0.003
  220. Cerebral Embolic Protection and Outcomes of Transcatheter Aortic Valve Replacement: Results From the Transcatheter Valve Therapy Registry. Circulation. 2021 06 08; 143(23):2229-2240.
    View in: PubMed
    Score: 0.003
  221. Variations in the Course of the Carotid Arteries in Patients with Retropharyngeal Parathyroid Adenomas. AJNR Am J Neuroradiol. 2021 04; 42(4):749-752.
    View in: PubMed
    Score: 0.003
  222. Association Between County-Level Change in Economic Prosperity and Change in Cardiovascular Mortality Among Middle-aged US Adults. JAMA. 2021 02 02; 325(5):445-453.
    View in: PubMed
    Score: 0.003
  223. Rural-Urban Disparities In All-Cause Mortality Among Low-Income Medicare Beneficiaries, 2004-17. Health Aff (Millwood). 2021 02; 40(2):289-296.
    View in: PubMed
    Score: 0.003
  224. Rationale and Design of the SAFE-PAD Study. Circ Cardiovasc Qual Outcomes. 2021 01; 14(1):e007040.
    View in: PubMed
    Score: 0.003
  225. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. J Endovasc Ther. 2021 Apr; 28(2):246-254.
    View in: PubMed
    Score: 0.003
  226. Assessing health-related quality of life among patients with peripheral artery disease: A review of the literature and focus on patient-reported outcome measures. Vasc Med. 2021 06; 26(3):317-325.
    View in: PubMed
    Score: 0.003
  227. Association of Acute Procedural Results With Long-Term Outcomes After CTO PCI. JACC Cardiovasc Interv. 2021 02 08; 14(3):278-288.
    View in: PubMed
    Score: 0.003
  228. Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. Rev Esp Cardiol (Engl Ed). 2021 Dec; 74(12):1023-1031.
    View in: PubMed
    Score: 0.003
  229. Intermediate procedural and health status outcomes and the clinical care pathways after chronic total occlusion angioplasty: A report from the OPEN-CTO (outcomes, patient health status, and efficiency in chronic total occlusion hybrid procedures) study. Catheter Cardiovasc Interv. 2021 10; 98(4):626-635.
    View in: PubMed
    Score: 0.003
  230. Response by Kazi et al to Letter Regarding Article, "Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy". Circulation. 2020 10 13; 142(15):e212-e213.
    View in: PubMed
    Score: 0.002
  231. Trends and Outcomes of Restenosis After Coronary Stent Implantation in the United States. J Am Coll Cardiol. 2020 09 29; 76(13):1521-1531.
    View in: PubMed
    Score: 0.002
  232. Medicaid Expansion and Ventricular Assist Device Implantation: An Analysis of the INTERMACS Registry. J Am Coll Cardiol. 2020 09 22; 76(12):1501-1502.
    View in: PubMed
    Score: 0.002
  233. Association Between 90-Minute Door-to-Balloon Time, Selective Exclusion of Myocardial Infarction Cases, and Access Site Choice: Insights From the Cardiac Care Outcomes Assessment Program (COAP) in Washington State. Circ Cardiovasc Interv. 2020 09; 13(9):e009179.
    View in: PubMed
    Score: 0.002
  234. Outcomes of retrograde chronic total occlusion percutaneous coronary intervention: A report from the OPEN-CTO registry. Catheter Cardiovasc Interv. 2021 05 01; 97(6):1162-1173.
    View in: PubMed
    Score: 0.002
  235. Community-Level Factors Associated With Racial And Ethnic Disparities In COVID-19 Rates In Massachusetts. Health Aff (Millwood). 2020 11; 39(11):1984-1992.
    View in: PubMed
    Score: 0.002
  236. Incidence, Prediction, and Causes of Unplanned 30-Day Hospital Admission After Ambulatory Procedures. Anesth Analg. 2020 08; 131(2):497-507.
    View in: PubMed
    Score: 0.002
  237. Performance of Hospitals When Assessing Disease-Based Mortality Compared With Procedural Mortality for Patients With Acute Myocardial Infarction. JAMA Cardiol. 2020 07 01; 5(7):765-772.
    View in: PubMed
    Score: 0.002
  238. Equipment utilization in chronic total occlusion percutaneous coronary interventions: Insights from the PROGRESS-CTO registry. Catheter Cardiovasc Interv. 2021 03; 97(4):658-667.
    View in: PubMed
    Score: 0.002
  239. Association of Homelessness with Hospital Readmissions-an Analysis of Three Large States. J Gen Intern Med. 2020 09; 35(9):2576-2583.
    View in: PubMed
    Score: 0.002
  240. Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement: Variation in Practice and Outcomes. JACC Cardiovasc Interv. 2020 06 08; 13(11):1277-1287.
    View in: PubMed
    Score: 0.002
  241. Comparison of Reperfusion Strategies for ST-Segment-Elevation Myocardial Infarction: A Multivariate Network Meta-analysis. J Am Heart Assoc. 2020 06 16; 9(12):e015186.
    View in: PubMed
    Score: 0.002
  242. SCAI position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheter Cardiovasc Interv. 2020 08; 96(2):346-362.
    View in: PubMed
    Score: 0.002
  243. Variation in COVID-19 Hospitalizations and Deaths Across New York City Boroughs. JAMA. 2020 Jun 02; 323(21):2192-2195.
    View in: PubMed
    Score: 0.002
  244. Performance in Federal Value-Based Programs of Hospitals Recognized by the American Heart Association and American College of Cardiology for High-Quality Heart Failure and Acute Myocardial Infarction Care. JAMA Cardiol. 2020 05 01; 5(5):515-521.
    View in: PubMed
    Score: 0.002
  245. Multidisciplinary Heart Team Approach for Complex Coronary Artery Disease: Single Center Clinical Presentation. J Am Heart Assoc. 2020 04 21; 9(8):e014738.
    View in: PubMed
    Score: 0.002
  246. Trends and predictors of early ablation for Atrial Fibrillation in a Nationwide population under age 65: a retrospective observational study. BMC Cardiovasc Disord. 2020 04 06; 20(1):161.
    View in: PubMed
    Score: 0.002
  247. Database Inaccuracies and Disparities in Care Among Homeless Adults Hospitalized for Cardiovascular Conditions-Reply. JAMA Intern Med. 2020 04 01; 180(4):614-615.
    View in: PubMed
    Score: 0.002
  248. Association of Outpatient Practice-Level Socioeconomic Disadvantage With Quality of Care and Outcomes Among Older Adults With Coronary Artery Disease: Implications for Value-Based Payment. Circ Cardiovasc Qual Outcomes. 2020 04; 13(4):e005977.
    View in: PubMed
    Score: 0.002
  249. Temporal Trends in Chronic Total Occlusion Percutaneous Coronary Interventions: Insights From the PROGRESS-CTO Registry. J Invasive Cardiol. 2020 Apr; 32(4):153-160.
    View in: PubMed
    Score: 0.002
  250. AF Ablation Outcomes: Real World or Fun House Mirror? J Am Coll Cardiol. 2020 03 17; 75(10):1243.
    View in: PubMed
    Score: 0.002
  251. Mortality and Hospitalizations for Dually Enrolled and Nondually Enrolled Medicare Beneficiaries Aged 65 Years or Older, 2004 to 2017. JAMA. 2020 03 10; 323(10):961-969.
    View in: PubMed
    Score: 0.002
  252. Disparities in Care and Mortality Among Homeless Adults Hospitalized for Cardiovascular Conditions. JAMA Intern Med. 2020 03 01; 180(3):357-366.
    View in: PubMed
    Score: 0.002
  253. Retrograde Chronic Total Occlusion Percutaneous Coronary Intervention via Saphenous Vein Graft. JACC Cardiovasc Interv. 2020 02 24; 13(4):517-526.
    View in: PubMed
    Score: 0.002
  254. Anticoagulation and amiodarone for new atrial fibrillation after coronary artery bypass grafting: Prescription patterns and 30-day outcomes in the United States and Canada. J Thorac Cardiovasc Surg. 2021 Aug; 162(2):616-624.e3.
    View in: PubMed
    Score: 0.002
  255. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data. J Am Heart Assoc. 2020 02 18; 9(4):e013606.
    View in: PubMed
    Score: 0.002
  256. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020 04 14; 141(15):1214-1224.
    View in: PubMed
    Score: 0.002
  257. Suitability of elderly adult hospital readmission rates for profiling readmissions in younger adult and pediatric populations. Health Serv Res. 2020 04; 55(2):277-287.
    View in: PubMed
    Score: 0.002
  258. Relation of Frailty to Outcomes After Catheter Ablation of Atrial Fibrillation. Am J Cardiol. 2020 05 01; 125(9):1317-1323.
    View in: PubMed
    Score: 0.002
  259. Association between procedure appropriateness and patient-reported outcomes after percutaneous coronary intervention. Heart. 2020 03; 106(6):441-446.
    View in: PubMed
    Score: 0.002
  260. The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). Angiology. 2020 03; 71(3):274-280.
    View in: PubMed
    Score: 0.002
  261. Readmissions after acute type B aortic dissection. J Vasc Surg. 2020 07; 72(1):73-83.e2.
    View in: PubMed
    Score: 0.002
  262. Utilization and Outcomes of Thrombolytic Therapy for Acute Pulmonary Embolism: A Nationwide Cohort Study. Chest. 2020 03; 157(3):645-653.
    View in: PubMed
    Score: 0.002
  263. A Need For Long-Term Results of LMCA-CTO-PCI. J Invasive Cardiol. 2019 11; 31(11):E342.
    View in: PubMed
    Score: 0.002
  264. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). Am J Cardiol. 2019 12 15; 124(12):1813-1820.
    View in: PubMed
    Score: 0.002
  265. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J. 2019 08 14; 40(31):2632-2653.
    View in: PubMed
    Score: 0.002
  266. Guiding Principles for Chronic Total Occlusion Percutaneous Coronary Intervention. Circulation. 2019 07 30; 140(5):420-433.
    View in: PubMed
    Score: 0.002
  267. Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry. Am Heart J. 2019 10; 216:53-61.
    View in: PubMed
    Score: 0.002
  268. Impact of concomitant treatment of non-chronic total occlusion lesions at the time of chronic total occlusion intervention. Int J Cardiol. 2020 01 15; 299:75-80.
    View in: PubMed
    Score: 0.002
  269. Association of Medicaid Expansion With Cardiovascular Mortality. JAMA Cardiol. 2019 07 01; 4(7):671-679.
    View in: PubMed
    Score: 0.002
  270. Left Main Chronic Total Occlusion Percutaneous Coronary Intervention: A Case Series. J Invasive Cardiol. 2019 Jul; 31(7):E220-E225.
    View in: PubMed
    Score: 0.002
  271. Intensive care use and mortality among patients with ST elevation myocardial infarction: retrospective cohort study. BMJ. 2019 06 04; 365:l1927.
    View in: PubMed
    Score: 0.002
  272. Etiologies, trends, and predictors of readmission in ST-elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. Catheter Cardiovasc Interv. 2019 Dec 01; 94(7):905-914.
    View in: PubMed
    Score: 0.002
  273. Uptake of Drug-Eluting Bioresorbable Vascular Scaffolds in Clinical Practice: An NCDR Registry to Practice Project. JAMA Cardiol. 2019 06 01; 4(6):564-568.
    View in: PubMed
    Score: 0.002
  274. Landscape of Cardiovascular Device Registries in the United States. J Am Heart Assoc. 2019 06 04; 8(11):e012756.
    View in: PubMed
    Score: 0.002
  275. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation. 2019 07 16; 140(3):240-261.
    View in: PubMed
    Score: 0.002
  276. The Hospital Readmissions Reduction Program - Time for a Reboot. N Engl J Med. 2019 Jun 13; 380(24):2289-2291.
    View in: PubMed
    Score: 0.002
  277. Hospital-Specific Mortality for Acute Myocardial Infarction Versus Emergency Percutaneous Coronary Intervention in New York State. JACC Cardiovasc Interv. 2019 05 13; 12(9):898-899.
    View in: PubMed
    Score: 0.002
  278. Effect of Public Reporting on the Utilization of Coronary Angiography After Out-of-Hospital Cardiac Arrest. Circ Cardiovasc Interv. 2019 04; 12(4):e007564.
    View in: PubMed
    Score: 0.002
  279. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Interventions in Patients With Prior Coronary Artery Bypass Graft Surgery. Circ Cardiovasc Interv. 2019 03; 12(3):e007338.
    View in: PubMed
    Score: 0.002
  280. Procedural Outcomes of Percutaneous Coronary Interventions for Chronic Total Occlusions Via the Radial Approach: Insights From an International Chronic Total Occlusion Registry. JACC Cardiovasc Interv. 2019 02 25; 12(4):346-358.
    View in: PubMed
    Score: 0.002
  281. Usefulness of Atherectomy in Chronic Total Occlusion Interventions (from the PROGRESS-CTO Registry). Am J Cardiol. 2019 05 01; 123(9):1422-1428.
    View in: PubMed
    Score: 0.002
  282. Association of State Medicaid Expansion With Quality of Care and Outcomes for Low-Income Patients Hospitalized With Acute Myocardial Infarction. JAMA Cardiol. 2019 02 01; 4(2):120-127.
    View in: PubMed
    Score: 0.002
  283. Frequency and Outcomes of Ad Hoc Versus Planned Chronic Total Occlusion Percutaneous Coronary Intervention: Multicenter Experience. J Invasive Cardiol. 2019 May; 31(5):133-139.
    View in: PubMed
    Score: 0.002
  284. Treating Symptomatic Aortic Stenosis With Transcatheter Aortic Valve Replacement: Is There Time to Wait? J Am Heart Assoc. 2019 01 08; 8(1):e011527.
    View in: PubMed
    Score: 0.002
  285. Trends, Causes, and Outcomes of Hospitalizations for Homeless Individuals: A Retrospective Cohort Study. Med Care. 2019 01; 57(1):21-27.
    View in: PubMed
    Score: 0.002
  286. Comparison Between Traditional and Guide-Catheter Extension Reverse Controlled Antegrade Dissection and Retrograde Tracking: Insights From the PROGRESS-CTO Registry. J Invasive Cardiol. 2019 01; 31(1):27-34.
    View in: PubMed
    Score: 0.002
  287. Causes and predictors of early readmission after percutaneous coronary intervention among patients discharged on oral anticoagulant therapy. PLoS One. 2018; 13(10):e0205457.
    View in: PubMed
    Score: 0.002
  288. In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention in Patients With Chronic Kidney Disease. J Invasive Cardiol. 2018 11; 30(11):E113-E121.
    View in: PubMed
    Score: 0.002
  289. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. Am Heart J. 2018 11; 205:110-117.
    View in: PubMed
    Score: 0.002
  290. Benefit and Risk of Prolonged DAPT After Coronary Stenting in Women. Circ Cardiovasc Interv. 2018 08; 11(8):e005308.
    View in: PubMed
    Score: 0.002
  291. Prevalence and Outcomes of Percutaneous Coronary Interventions for Ostial Chronic Total Occlusions: Insights From a Multicenter Chronic Total Occlusion Registry. Can J Cardiol. 2018 10; 34(10):1264-1274.
    View in: PubMed
    Score: 0.002
  292. Public Reporting of Percutaneous Coronary Intervention Outcomes: Moving Beyond the Status Quo. JAMA Cardiol. 2018 07 01; 3(7):635-640.
    View in: PubMed
    Score: 0.002
  293. Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study. Catheter Cardiovasc Interv. 2018 11 01; 92(5):E348-E355.
    View in: PubMed
    Score: 0.002
  294. In-hospital Outcomes of Attempting More Than One Chronic Total Coronary Occlusion Through Percutaneous Intervention During the Same Procedure. Am J Cardiol. 2018 08 01; 122(3):381-387.
    View in: PubMed
    Score: 0.002
  295. The Hybrid Approach to Chronic Total Occlusion Percutaneous Coronary Intervention: Update From the PROGRESS CTO Registry. JACC Cardiovasc Interv. 2018 07 23; 11(14):1325-1335.
    View in: PubMed
    Score: 0.002
  296. Acute Myocardial Infarction Mortality During Dates of National Interventional Cardiology Meetings. J Am Heart Assoc. 2018 03 09; 7(6).
    View in: PubMed
    Score: 0.002
  297. Mechanical Circulatory Support in Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter U.S. Registry. J Invasive Cardiol. 2018 03; 30(3):81-87.
    View in: PubMed
    Score: 0.002
  298. Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. Circ Cardiovasc Interv. 2018 01; 11(1):e005795.
    View in: PubMed
    Score: 0.002
  299. Personal and Professional Characteristics of U.S. Dual-Boarded Critical Care Cardiologists in 2015. Crit Care Med. 2017 Dec; 45(12):e1292-e1296.
    View in: PubMed
    Score: 0.002
  300. Retrograde CTO-PCI of Native Coronary Arteries Via Left Internal Mammary Artery Grafts: Insights From a Multicenter U.S. Registry. J Invasive Cardiol. 2018 03; 30(3):89-96.
    View in: PubMed
    Score: 0.002
  301. Variation in the Adoption of Transradial Access for ST-Segment Elevation Myocardial Infarction: Insights From the NCDR CathPCI Registry. JACC Cardiovasc Interv. 2017 11 27; 10(22):2242-2254.
    View in: PubMed
    Score: 0.002
  302. Current Perspectives and Practices on Chronic Total Occlusion Percutaneous Coronary Interventions. J Invasive Cardiol. 2018 02; 30(2):43-50.
    View in: PubMed
    Score: 0.002
  303. Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: An NCDR Research to Practice (R2P) project. Am Heart J. 2018 01; 195:151-152.
    View in: PubMed
    Score: 0.002
  304. Residual Angina After Elective Percutaneous Coronary Intervention in Patients With Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2017 Sep; 10(9).
    View in: PubMed
    Score: 0.002
  305. Early Procedural and Health Status Outcomes After Chronic Total Occlusion Angioplasty: A Report From the OPEN-CTO Registry (Outcomes, Patient Health Status, and Efficiency in Chronic Total Occlusion Hybrid Procedures). JACC Cardiovasc Interv. 2017 08 14; 10(15):1523-1534.
    View in: PubMed
    Score: 0.002
  306. Reply: Duration of the Double Antiplatelet Therapy in Patients With Coronary and Peripheral Arterial Disease: The Key Might Be in the Type of Drug. JACC Cardiovasc Interv. 2017 07 24; 10(14):1468-1469.
    View in: PubMed
    Score: 0.002
  307. Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention. Am J Cardiol. 2017 Oct 15; 120(8):1285-1292.
    View in: PubMed
    Score: 0.002
  308. Effect of Short Procedural Duration With Bivalirudin on Increased Risk of Acute Stent Thrombosis in Patients With STEMI: A Secondary Analysis of the HORIZONS-AMI Randomized Clinical Trial. JAMA Cardiol. 2017 06 01; 2(6):673-677.
    View in: PubMed
    Score: 0.002
  309. Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry. JACC Cardiovasc Interv. 2017 06 12; 10(11):1102-1111.
    View in: PubMed
    Score: 0.002
  310. The Impact of Proximal Vessel Tortuosity on the Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Invasive Cardiol. 2017 Aug; 29(8):264-270.
    View in: PubMed
    Score: 0.002
  311. Novel Method for Exchange of Impella Circulatory Assist Catheter: The "Trojan Horse" Technique. J Invasive Cardiol. 2017 Jul; 29(7):250-252.
    View in: PubMed
    Score: 0.002
  312. Extended Duration Dual Antiplatelet Therapy After Coronary Stenting Among Patients With Peripheral Arterial Disease: A Subanalysis of the Dual Antiplatelet Therapy Study. JACC Cardiovasc Interv. 2017 05 08; 10(9):942-954.
    View in: PubMed
    Score: 0.002
  313. Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. JAMA Cardiol. 2017 05 01; 2(5):478-487.
    View in: PubMed
    Score: 0.002
  314. Impact of Calcium on Chronic Total Occlusion Percutaneous Coronary Interventions. Am J Cardiol. 2017 07 01; 120(1):40-46.
    View in: PubMed
    Score: 0.002
  315. Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). Circulation. 2017 May 02; 135(18):1720-1732.
    View in: PubMed
    Score: 0.002
  316. Time-Course of Cause-Specific Hospital Admissions During Snowstorms: An Analysis of Electronic Medical Records From Major Hospitals in Boston, Massachusetts. Am J Epidemiol. 2017 02 15; 185(4):283-294.
    View in: PubMed
    Score: 0.002
  317. Sex Differences in Faculty Rank Among Academic Cardiologists in the United States. Circulation. 2017 02 07; 135(6):506-517.
    View in: PubMed
    Score: 0.002
  318. The Impact of Age and Sex on In-Hospital Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention. J Invasive Cardiol. 2017 Apr; 29(4):116-122.
    View in: PubMed
    Score: 0.002
  319. Approaches to percutaneous coronary intervention of right coronary artery chronic total occlusions: insights from a multicentre US registry. EuroIntervention. 2016 Dec 10; 12(11):e1326-e1335.
    View in: PubMed
    Score: 0.002
  320. Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. Thromb Haemost. 2017 01 26; 117(2):246-251.
    View in: PubMed
    Score: 0.002
  321. Predictors of Excess Patient Radiation Exposure During Chronic Total Occlusion Coronary Intervention: Insights From a Contemporary Multicentre Registry. Can J Cardiol. 2017 04; 33(4):478-484.
    View in: PubMed
    Score: 0.002
  322. 2016 Revision of the SCAI position statement on public reporting. Catheter Cardiovasc Interv. 2017 Feb 01; 89(2):269-279.
    View in: PubMed
    Score: 0.002
  323. Coronary artery spatial distribution of chronic total occlusions: Insights from a large US registry. Catheter Cardiovasc Interv. 2017 Jul; 90(1):23-30.
    View in: PubMed
    Score: 0.002
  324. Impact of diabetes mellitus on acute outcomes of percutaneous coronary intervention in chronic total occlusions: insights from a US multicentre registry. Diabet Med. 2017 04; 34(4):558-562.
    View in: PubMed
    Score: 0.002
  325. Implications of Public Reporting of Risk-Adjusted Mortality Following Percutaneous Coronary Intervention: Misperceptions and Potential Consequences for High-Risk Patients Including Nonsurgical Patients. JACC Cardiovasc Interv. 2016 10 24; 9(20):2077-2085.
    View in: PubMed
    Score: 0.002
  326. Development and Validation of a Scoring System for Predicting Periprocedural Complications During Percutaneous Coronary Interventions of Chronic Total Occlusions: The Prospective Global Registry for the Study of Chronic Total Occlusion Intervention (PROGRESS CTO) Complications Score. J Am Heart Assoc. 2016 10 11; 5(10).
    View in: PubMed
    Score: 0.002
  327. Impact of Proximal Cap Ambiguity on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Multicenter US Registry. J Invasive Cardiol. 2016 Oct; 28(10):391-396.
    View in: PubMed
    Score: 0.002
  328. Real-time fusion of coronary CT angiography with x-ray fluoroscopy during chronic total occlusion PCI. Eur Radiol. 2017 Jun; 27(6):2464-2473.
    View in: PubMed
    Score: 0.002
  329. Prevalence, indications and management of balloon uncrossable chronic total occlusions: Insights from a contemporary multicenter US registry. Catheter Cardiovasc Interv. 2017 Jul; 90(1):12-20.
    View in: PubMed
    Score: 0.002
  330. Comparing Inverse Probability of Treatment Weighting and Instrumental Variable Methods for the Evaluation of Adenosine Diphosphate Receptor Inhibitors After Percutaneous Coronary Intervention. JAMA Cardiol. 2016 Sep 01; 1(6):655-65.
    View in: PubMed
    Score: 0.002
  331. Impact of Optimal Medical Therapy in the Dual Antiplatelet Therapy Study. Circulation. 2016 Oct 04; 134(14):989-998.
    View in: PubMed
    Score: 0.002
  332. Clinical Interventions to Reduce Preventable Hospital Readmission After Percutaneous Coronary Intervention. Circ Cardiovasc Qual Outcomes. 2016 09; 9(5):600-4.
    View in: PubMed
    Score: 0.002
  333. Comparison of various scores for predicting success of chronic total occlusion percutaneous coronary intervention. Int J Cardiol. 2016 Dec 01; 224:50-56.
    View in: PubMed
    Score: 0.002
  334. Use of Intravascular Imaging During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Am Heart Assoc. 2016 08 20; 5(8).
    View in: PubMed
    Score: 0.002
  335. Contrast Utilization During Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary Multicenter Registry. J Invasive Cardiol. 2016 Jul; 28(7):288-94.
    View in: PubMed
    Score: 0.002
  336. National Trends in Hospitalizations of Adults With Tetralogy of Fallot. Am J Cardiol. 2016 09 15; 118(6):906-911.
    View in: PubMed
    Score: 0.002
  337. Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data. Catheter Cardiovasc Interv. 2016 Nov; 88(5):697-707.
    View in: PubMed
    Score: 0.002
  338. Outcomes With the Use of the Retrograde Approach for Coronary Chronic Total Occlusion Interventions in a Contemporary Multicenter US Registry. Circ Cardiovasc Interv. 2016 06; 9(6).
    View in: PubMed
    Score: 0.002
  339. Understanding physician-level barriers to the use of individualized risk estimates in percutaneous coronary intervention. Am Heart J. 2016 08; 178:190-7.
    View in: PubMed
    Score: 0.002
  340. Guidewire and microcatheter utilization patterns during antegrade wire escalation in chronic total occlusion percutaneous coronary intervention: Insights from a contemporary multicenter registry. Catheter Cardiovasc Interv. 2017 Mar 01; 89(4):E90-E98.
    View in: PubMed
    Score: 0.002
  341. Effect of Lesion Age on Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From a Contemporary US Multicenter Registry. Can J Cardiol. 2016 12; 32(12):1433-1439.
    View in: PubMed
    Score: 0.002
  342. Use of antegrade dissection re-entry in coronary chronic total occlusion percutaneous coronary intervention in a contemporary multicenter registry. Int J Cardiol. 2016 Jul 01; 214:428-37.
    View in: PubMed
    Score: 0.002
  343. DAPT Score Utility for Risk Prediction in Patients With or Without Previous Myocardial Infarction. J Am Coll Cardiol. 2016 May 31; 67(21):2492-502.
    View in: PubMed
    Score: 0.002
  344. Diabetes Mellitus and Prevention of Late Myocardial Infarction After Coronary Stenting in the Randomized Dual Antiplatelet Therapy Study. Circulation. 2016 May 03; 133(18):1772-82.
    View in: PubMed
    Score: 0.002
  345. Editorial Commentary: Hard questions for mobile technology in cardiology. Trends Cardiovasc Med. 2016 May; 26(4):387-8.
    View in: PubMed
    Score: 0.002
  346. Effect of Previous Failure on Subsequent Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention (from a Contemporary Multicenter Registry). Am J Cardiol. 2016 Apr 15; 117(8):1267-71.
    View in: PubMed
    Score: 0.002
  347. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):447-54.
    View in: PubMed
    Score: 0.002
  348. Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC Cardiovasc Interv. 2016 Jan 25; 9(2):138-47.
    View in: PubMed
    Score: 0.002
  349. Development and Validation of a Novel Scoring System for Predicting Technical Success of Chronic Total Occlusion Percutaneous Coronary Interventions: The PROGRESS CTO (Prospective Global Registry for the Study of Chronic Total Occlusion Intervention) Score. JACC Cardiovasc Interv. 2016 Jan 11; 9(1):1-9.
    View in: PubMed
    Score: 0.002
  350. Coronary CT angiography for myocardial infarction: case studies of the Massachusetts General Hospital. Coron Artery Dis. 2016 Jan; 27(1):72-3.
    View in: PubMed
    Score: 0.002
  351. Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. Curr Atheroscler Rep. 2016 Jan; 18(1):5.
    View in: PubMed
    Score: 0.002
  352. Transradial Versus Transfemoral Access in Patients Undergoing Rescue Percutaneous Coronary Intervention After Fibrinolytic Therapy. JACC Cardiovasc Interv. 2015 Dec 21; 8(14):1868-76.
    View in: PubMed
    Score: 0.002
  353. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016 Jan 26; 133(4):e38-360.
    View in: PubMed
    Score: 0.002
  354. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016 Jan 21; 37(4):378-85.
    View in: PubMed
    Score: 0.002
  355. Differences Among Cardiologists in Rates of Positive Coronary Angiograms. J Am Heart Assoc. 2015 Oct 16; 4(10):e002393.
    View in: PubMed
    Score: 0.002
  356. Stent Thrombosis in Drug-Eluting or Bare-Metal Stents in Patients Receiving Dual Antiplatelet Therapy. JACC Cardiovasc Interv. 2015 Oct; 8(12):1552-62.
    View in: PubMed
    Score: 0.002
  357. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. JAMA Intern Med. 2015 Jul; 175(7):1104-9.
    View in: PubMed
    Score: 0.002
  358. Clinical Utility of the Japan-Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions: Results from a Multicenter Registry. Circ Cardiovasc Interv. 2015 Jul; 8(7):e002171.
    View in: PubMed
    Score: 0.002
  359. Application and outcomes of a hybrid approach to chronic total occlusion percutaneous coronary intervention in a contemporary multicenter US registry. Int J Cardiol. 2015 Nov 01; 198:222-8.
    View in: PubMed
    Score: 0.002
  360. National Trends in Hospitalizations for Patients With Single-Ventricle Anatomy. Am J Cardiol. 2015 Sep 01; 116(5):773-8.
    View in: PubMed
    Score: 0.002
  361. Balancing Long-Term Risks of Ischemic and Bleeding Complications After Percutaneous Coronary Intervention With Drug-Eluting Stents. Am J Cardiol. 2015 Sep 01; 116(5):686-93.
    View in: PubMed
    Score: 0.002
  362. Association of body mass index with mortality and cardiovascular events for patients with coronary artery disease: a systematic review and meta-analysis. Heart. 2015 Oct; 101(20):1631-8.
    View in: PubMed
    Score: 0.002
  363. Standardized Outcome Measurement for Patients With Coronary Artery Disease: Consensus From the International Consortium for Health Outcomes Measurement (ICHOM). J Am Heart Assoc. 2015 May 19; 4(5).
    View in: PubMed
    Score: 0.002
  364. Duration of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2015 04 02; 372(14):1373-4.
    View in: PubMed
    Score: 0.002
  365. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). Am J Cardiol. 2015 Jun 15; 115(12):1678-84.
    View in: PubMed
    Score: 0.002
  366. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the dual antiplatelet therapy randomized clinical trial. JAMA. 2015 Mar 17; 313(11):1113-21.
    View in: PubMed
    Score: 0.002
  367. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015 Jan 27; 131(4):e29-322.
    View in: PubMed
    Score: 0.002
  368. The data extraction and longitudinal trend analysis network study of distributed automated postmarket cardiovascular device safety surveillance. Circ Cardiovasc Qual Outcomes. 2015 Jan; 8(1):38-46.
    View in: PubMed
    Score: 0.002
  369. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014 Dec 04; 371(23):2155-66.
    View in: PubMed
    Score: 0.002
  370. Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents. Am Heart J. 2015 Feb; 169(2):222-233.e5.
    View in: PubMed
    Score: 0.002
  371. The challenges of success: maintaining access to high-quality percutaneous coronary intervention in the face of declining procedural volumes. Circulation. 2014 Oct 14; 130(16):1343-5.
    View in: PubMed
    Score: 0.002
  372. Public reporting of PCI outcomes: for better or for worse. Curr Cardiol Rep. 2014 Jul; 16(7):500.
    View in: PubMed
    Score: 0.002
  373. Usefulness of postmarket studies to evaluate long-term safety of coronary eluting stents (from the ENDEAVOR and PROTECT Programs). Am J Cardiol. 2014 Aug 15; 114(4):528-33.
    View in: PubMed
    Score: 0.002
  374. Adherence to dual antiplatelet therapy after coronary stenting: a systematic review. Clin Cardiol. 2014 Aug; 37(8):505-13.
    View in: PubMed
    Score: 0.002
  375. Risk adjustment of ischemic stroke outcomes for comparing hospital performance: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014 Mar; 45(3):918-44.
    View in: PubMed
    Score: 0.002
  376. Usefulness of the Seattle Heart Failure Model to identify adults with congenital heart disease at high risk of poor outcome. Am J Cardiol. 2014 Mar 01; 113(5):865-70.
    View in: PubMed
    Score: 0.002
  377. A plasma long-chain acylcarnitine predicts cardiovascular mortality in incident dialysis patients. J Am Heart Assoc. 2013 Dec 05; 2(6):e000542.
    View in: PubMed
    Score: 0.002
  378. Procedural variation in the performance of primary percutaneous coronary intervention for ST-elevation myocardial infarction: a SCAI-based survey study of US interventional cardiologists. Catheter Cardiovasc Interv. 2014 Apr 01; 83(5):721-6.
    View in: PubMed
    Score: 0.002
  379. Unprotected carotid artery stenting in modern practice. Catheter Cardiovasc Interv. 2014 Mar 01; 83(4):595-602.
    View in: PubMed
    Score: 0.002
  380. Frequency of the use of low- versus high-dose aspirin in dual antiplatelet therapy after percutaneous coronary intervention (from the Dual Antiplatelet Therapy study). Am J Cardiol. 2014 Apr 01; 113(7):1146-52.
    View in: PubMed
    Score: 0.002
  381. Cardiovascular care facts: a report from the national cardiovascular data registry: 2011. J Am Coll Cardiol. 2013 Nov 19; 62(21):1931-1947.
    View in: PubMed
    Score: 0.002
  382. Strategies for postmarketing surveillance of drugs and devices in patients with ESRD undergoing dialysis. Clin J Am Soc Nephrol. 2013 Dec; 8(12):2213-20.
    View in: PubMed
    Score: 0.002
  383. Features of coronary plaque in patients with metabolic syndrome and diabetes mellitus assessed by 3-vessel optical coherence tomography. Circ Cardiovasc Imaging. 2013 Sep; 6(5):665-73.
    View in: PubMed
    Score: 0.002
  384. A combined epidemiologic and metabolomic approach improves CKD prediction. J Am Soc Nephrol. 2013 Jul; 24(8):1330-8.
    View in: PubMed
    Score: 0.001
  385. Caesarian dissection: a case of chest pain and dyspnea during delivery. Circulation. 2013 Apr 09; 127(14):1530-5.
    View in: PubMed
    Score: 0.001
  386. Hemorrhagic and ischemic outcomes after bivalirudin versus unfractionated heparin during carotid artery stenting: a propensity score analysis from the NCDR. Circ Cardiovasc Interv. 2013 Apr; 6(2):131-8.
    View in: PubMed
    Score: 0.001
  387. Nuisance bleeding with prolonged dual antiplatelet therapy after acute myocardial infarction and its impact on health status. J Am Coll Cardiol. 2013 May 28; 61(21):2130-8.
    View in: PubMed
    Score: 0.001
  388. Model feedback in Bayesian propensity score estimation. Biometrics. 2013 Mar; 69(1):263-73.
    View in: PubMed
    Score: 0.001
  389. Risk prediction for adverse events after carotid artery stenting in higher surgical risk patients. Stroke. 2012 Dec; 43(12):3218-24.
    View in: PubMed
    Score: 0.001
  390. Comparison of nonculprit coronary plaque characteristics between patients with and without diabetes: a 3-vessel optical coherence tomography study. JACC Cardiovasc Interv. 2012 Nov; 5(11):1150-8.
    View in: PubMed
    Score: 0.001
  391. Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program. Am J Cardiol. 2012 Oct 15; 110(8):1169-74.
    View in: PubMed
    Score: 0.001
  392. Comparison of incidence and time course of neoatherosclerosis between bare metal stents and drug-eluting stents using optical coherence tomography. Am J Cardiol. 2012 Oct 01; 110(7):933-9.
    View in: PubMed
    Score: 0.001
  393. Association between leukocyte telomere length and drug-eluting stent strut coverage by optical coherence tomography. J Am Coll Cardiol. 2012 Jun 12; 59(24):2218-9.
    View in: PubMed
    Score: 0.001
  394. Nonculprit plaques in patients with acute coronary syndromes have more vulnerable features compared with those with non-acute coronary syndromes: a 3-vessel optical coherence tomography study. Circ Cardiovasc Imaging. 2012 Jul; 5(4):433-40.
    View in: PubMed
    Score: 0.001
  395. Percutaneous coronary interventions without on-site cardiac surgical backup. N Engl J Med. 2012 May 10; 366(19):1814-23.
    View in: PubMed
    Score: 0.001
  396. Surgical candidacy and selection biases in nonemergent left main stenting: implications for observational studies. JACC Cardiovasc Interv. 2011 Sep; 4(9):1020-7.
    View in: PubMed
    Score: 0.001
  397. Clinical factors and echocardiographic techniques related to the presence, size, and location of acoustic windows for leadless cardiac pacing. Europace. 2011 Dec; 13(12):1760-5.
    View in: PubMed
    Score: 0.001
  398. Anticoagulant agents in acute coronary syndromes. Curr Probl Cardiol. 2011 Apr; 36(4):127-68.
    View in: PubMed
    Score: 0.001
  399. Clinical referral patterns for carotid artery stenting versus carotid endarterectomy: results from the Carotid Artery Revascularization and Endarterectomy Registry. Circ Cardiovasc Interv. 2011 Feb 01; 4(1):88-94.
    View in: PubMed
    Score: 0.001
  400. Inadvertent femoral endarterectomy: a complication from a suture-based vascular closure device. J Vasc Access. 2011 Jan-Mar; 12(1):71-2.
    View in: PubMed
    Score: 0.001
  401. Safety and efficacy of the argatroban therapy during the early post-cardiac surgery period. J Thromb Thrombolysis. 2010 Oct; 30(3):276-80.
    View in: PubMed
    Score: 0.001
  402. Antiplatelet agents in acute coronary syndromes. Curr Probl Cardiol. 2010 Mar; 35(3):123-70.
    View in: PubMed
    Score: 0.001
  403. Calcium-triggered short-coupled polymorphous ventricular tachycardia. Pacing Clin Electrophysiol. 2010 Jan; 33(1):117-22.
    View in: PubMed
    Score: 0.001
  404. Efficacy and safety of argatroban in patients with heparin induced thrombocytopenia undergoing endovascular intervention for peripheral arterial disease. Catheter Cardiovasc Interv. 2008 Jul 01; 72(1):116-20.
    View in: PubMed
    Score: 0.001
  405. What is the optimal anticoagulation level with argatroban during percutaneous coronary intervention? Blood Coagul Fibrinolysis. 2008 Jul; 19(5):401-4.
    View in: PubMed
    Score: 0.001
  406. Episodic ventricular pacing with intact atrioventricular nodal function in a DDDR device: what is the rhythm and how can it be prevented? Heart Rhythm. 2008 Jun; 5(6):897-8.
    View in: PubMed
    Score: 0.001
  407. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol. 2007 Oct; 14(10):1152-62.
    View in: PubMed
    Score: 0.001
  408. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis. 2008 Apr; 25(2):214-8.
    View in: PubMed
    Score: 0.001
  409. Analysis of cardiac dimensions, mass and function in heart transplant recipients using 64-slice multi-detector computed tomography. J Heart Lung Transplant. 2007 May; 26(5):478-84.
    View in: PubMed
    Score: 0.001
  410. Prevalence of heparin/platelet factor 4 antibodies before and after cardiac surgery. Ann Thorac Surg. 2007 Feb; 83(2):592-7.
    View in: PubMed
    Score: 0.001
  411. Comparison of sixty-four-slice multidetector computed tomographic coronary angiography to coronary angiography with intravascular ultrasound for the detection of transplant vasculopathy. Am J Cardiol. 2006 Oct 01; 98(7):877-84.
    View in: PubMed
    Score: 0.001
  412. Prevalence of heparin-induced thrombocytopenia in patients undergoing cardiac catheterization. Am Heart J. 2006 Aug; 152(2):290.e1-7.
    View in: PubMed
    Score: 0.001
  413. Purification and characterization of human lymphoblast N-acetylglucosamine-1-phosphotransferase. Glycobiology. 1992 Apr; 2(2):119-25.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.